Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem Tissue Penetration in Severe Pancreatitis
NCT00318994Phase 4Completed
- Sponsor
- Pfizer
- Start
- Feb 2002
- Primary completion
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of meropenem in pancreatitis, sponsored by Pfizer. Primary endpoint: Meropenem pancreatic tissue penetration. Started Feb 2002; status: completed.
02
Drugs
meropenem
03
Conditions
pancreatitis
Beyond the preview
Go deeper on NCT00318994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00318994.